[go: up one dir, main page]

SMT202000248T1 - Derivati di estere di acido boronico ciclico e relativi usi terapeutici - Google Patents

Derivati di estere di acido boronico ciclico e relativi usi terapeutici

Info

Publication number
SMT202000248T1
SMT202000248T1 SM20200248T SMT202000248T SMT202000248T1 SM T202000248 T1 SMT202000248 T1 SM T202000248T1 SM 20200248 T SM20200248 T SM 20200248T SM T202000248 T SMT202000248 T SM T202000248T SM T202000248 T1 SMT202000248 T1 SM T202000248T1
Authority
SM
San Marino
Prior art keywords
preparation
acid ester
boronic acid
ester derivatives
therapeutic uses
Prior art date
Application number
SM20200248T
Other languages
English (en)
Inventor
Michael N Dudley
David C Griffith
Scott Hecker
Serge Boyer
Olga Rodny
Gavin Hirst
Raja Reddy
Maxim Totrov
Original Assignee
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45565270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202000248(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rempex Pharmaceuticals Inc filed Critical Rempex Pharmaceuticals Inc
Publication of SMT202000248T1 publication Critical patent/SMT202000248T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SM20200248T 2010-08-10 2011-08-08 Derivati di estere di acido boronico ciclico e relativi usi terapeutici SMT202000248T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37229610P 2010-08-10 2010-08-10
US201161488655P 2011-05-20 2011-05-20
EP18183968.9A EP3412676B1 (en) 2010-08-10 2011-08-08 Cyclic boronic acid ester derivatives, method for the preparation and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
SMT202000248T1 true SMT202000248T1 (it) 2020-07-08

Family

ID=45565270

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200248T SMT202000248T1 (it) 2010-08-10 2011-08-08 Derivati di estere di acido boronico ciclico e relativi usi terapeutici

Country Status (29)

Country Link
US (11) US8680136B2 (it)
EP (3) EP2603514B1 (it)
JP (4) JP6266978B2 (it)
KR (3) KR102087313B1 (it)
CN (1) CN103180328B (it)
AU (1) AU2011289615B2 (it)
BR (1) BR112013003045B1 (it)
CA (1) CA2807546C (it)
CL (1) CL2013000399A1 (it)
CO (1) CO6680667A2 (it)
CY (3) CY1123208T1 (it)
DK (2) DK2603514T3 (it)
ES (2) ES2691468T3 (it)
HR (1) HRP20200741T1 (it)
HU (4) HUE048859T2 (it)
IL (1) IL224564A (it)
LT (3) LT3412676T (it)
LU (2) LUC00168I2 (it)
MX (1) MX348653B (it)
MY (2) MY188960A (it)
NO (2) NO2019013I1 (it)
NZ (1) NZ607354A (it)
PL (2) PL2603514T3 (it)
PT (2) PT2603514T (it)
RS (1) RS60310B1 (it)
RU (1) RU2599791C2 (it)
SG (1) SG187757A1 (it)
SM (1) SMT202000248T1 (it)
WO (1) WO2012021455A1 (it)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
WO2013033461A1 (en) * 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
EP2814483A2 (en) * 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014052836A2 (en) 2012-09-27 2014-04-03 Dunman Paul M Methods and compositions for treating infection
WO2014089365A1 (en) 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Beta-lactamase inhibitors
EP2935228B9 (en) 2012-12-20 2017-12-06 Inception 2, Inc. Triazolone compounds and uses thereof
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008627A (es) * 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA3011999A1 (en) * 2013-05-03 2014-11-06 Microbiotix, Inc. Antimicrobial potentiators
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3140310B1 (en) * 2014-05-05 2019-08-07 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
KR20220065084A (ko) 2014-06-11 2022-05-19 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20170024087A (ko) 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN104447610A (zh) * 2014-11-21 2015-03-25 山东金城医药化工股份有限公司 高纯度头孢他啶侧链酸的制备方法
EP3233869B1 (en) * 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN107530364A (zh) 2015-04-24 2018-01-02 莱姆派克斯制药公司 治疗细菌感染的方法
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
ES2970715T3 (es) * 2016-12-22 2024-05-30 Prec Pharmaceuticals Inc Composiciones y métodos para inhibir la actividad de la arginasa
CA3048650A1 (en) 2017-01-09 2018-07-12 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3630782A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
CN111212843B (zh) 2017-10-11 2025-05-16 Qpex生物制药有限公司 硼酸衍生物及其合成
AU2018360502B2 (en) * 2017-11-01 2024-05-02 Melinta Therapeutics, Llc Synthesis of boronate ester derivatives and uses thereof
JP7329260B2 (ja) 2018-04-20 2023-08-18 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN111039965B (zh) * 2018-10-12 2020-12-01 新发药业有限公司 一种法硼巴坦的简便制备方法
WO2022182993A1 (en) * 2021-02-25 2022-09-01 Ohio State Innovation Foundation Liposomal formulations of boronic acid containing active agents
CN113214302B (zh) * 2021-04-23 2022-06-24 四川大学 一种抑制金属β-内酰胺酶和/或丝氨酸β-内酰胺酶的3-取代五元环状硼酸酯衍生物
WO2023082055A1 (zh) * 2021-11-09 2023-05-19 中国医学科学院医药生物技术研究所 包含β-内酰胺类化合物的药物组合物及其用途
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
FR2574070B1 (fr) 1984-11-30 1987-02-27 Stam Catalyseur de prise de mortiers d'anhydrite projetes a la lance, a resistance amelioree a un stockage a temperature et humidite elevees, et utilisation d'un tel catalyseur
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CA1283404C (en) 1986-07-01 1991-04-23 Shigeru Sanai Cephalosporin compounds, processes for their preparation and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
WO1998056392A1 (en) 1997-06-13 1998-12-17 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
AU2190400A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
HUP0202787A3 (en) 1999-09-25 2003-12-29 Smithkline Beecham Plc Piperazine derivatives as 5-ht1b antagonists, process for their preparation and pharmaceutical compositions containing them
WO2001030149A1 (en) 1999-10-28 2001-05-03 Merck & Co., Inc. Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
AU2001292732A1 (en) 2000-09-12 2002-03-26 Larry C. Blasczcak Beta-lactam analogs and uses therefor
DE60111757T2 (de) 2000-09-14 2006-04-27 Pantherix Ltd. 3-(Heteroarylacetamido)-2-oxoazetidin-1-sulfonsäure-derivate als antibakterielle Mittel
WO2002054931A2 (en) 2001-01-10 2002-07-18 Bristol Myers Squibb Company P Alpha-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
WO2003057144A2 (en) 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
CA2488785C (en) 2002-09-11 2012-07-03 Kureha Chemical Industry Company, Limited Amine compound and use thereof
EP3412696A1 (en) 2002-10-30 2018-12-12 Sumitomo Chemical Company, Limited High-molecular compounds and polymer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
JP2006511587A (ja) 2002-12-20 2006-04-06 ミジェニックス コーポレイション アデニンヌクレオチドトランスロカーゼ（ａｎｔ）リガンドならびにそれに関連する組成物および方法
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
WO2005033090A1 (ja) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited 芳香族化合物
ATE369370T1 (de) 2003-10-10 2007-08-15 Pfizer Prod Inc Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
RU2414906C2 (ru) 2005-02-16 2011-03-27 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы
ES2389565T3 (es) 2005-02-22 2012-10-29 Teva Pharmaceutical Industries Ltd. Rosuvastatina y sales de la misma carentes de alquiléter de rosuvatatina y un procedimiento para la preparación de las mismas
US9184428B2 (en) 2005-03-15 2015-11-10 Uchicago Argonne Llc Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
ES2373461T3 (es) 2005-12-07 2012-02-03 Basilea Pharmaceutica Ag Antibióticos útiles de monobactama.
DK1988779T5 (en) 2006-02-16 2016-10-10 Anacor Pharmaceuticals Inc SMALL boron MOLECULES AS ANTI-INFLAMMATORY AGENTS
EP2069347A2 (en) 2006-09-27 2009-06-17 Merck & Co., Inc. Novel inhibitors of beta-lactamase
RU2488394C2 (ru) 2007-03-23 2013-07-27 Базилеа Фармацойтика Аг Комбинированные лекарственные средства для лечения бактериальных инфекций
GB0719366D0 (en) 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
BRPI0820531A2 (pt) 2007-11-13 2012-07-10 Protez Pharmaceuticals Inc inibidores de beta-lactamase
DK2231667T3 (da) 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase-hæmmere
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2285384A4 (en) 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2009139834A1 (en) 2008-05-13 2009-11-19 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
JP2012512262A (ja) 2008-12-17 2012-05-31 アナコール ファーマシューティカルズ，インコーポレーテッド （ｓ）−３−アミノメチル−７−（３−ヒドロキシ−プロポキシ）−３ｈ−ベンゾ［ｃ］［１，２］オキサボロール−１−オールの多形体
WO2010075286A1 (en) 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
BRPI1010881A2 (pt) 2009-06-08 2016-05-31 California Capital Equity Llc derivados de triazina e suas aplicações terapêuticas.
MX2012001156A (es) 2009-07-28 2012-05-08 Anacor Pharmaceuticals Inc Moleculas que contienen boro trisustituidas.
US20120329770A1 (en) 2010-02-26 2012-12-27 Gary Igor Dmitrienko Cephalosporin derivatives useful as beta-lactamase inhibitors and compositions and methods of use thereof
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
JP5603487B2 (ja) 2010-06-10 2014-10-08 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド ヨウ化物の調製のためのプロセス
RU2599791C2 (ru) * 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
HUE027317T2 (en) 2010-10-26 2016-10-28 Mars Inc Boronates as arginase inhibitors
TW201221518A (en) 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
MX352652B (es) 2011-12-22 2017-12-04 Ares Trading Sa Inhibidores de inmunoproteasoma selectivos de derivados del acido alfa-amino boronico.
RU2014131370A (ru) 2012-01-09 2016-02-27 Юниверсити Оф Тромсё Терапевтические соединения, содержащие бор
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014089365A1 (en) 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Beta-lactamase inhibitors
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US8999885B2 (en) 2013-01-09 2015-04-07 General Electric Company Methods of activating charcoal resulting from biomass gasification
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014144380A1 (en) 2013-03-15 2014-09-18 Intrexon Corporation Boron-containing diacylhydrazines
EP3140310B1 (en) 2014-05-05 2019-08-07 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
KR20220065084A (ko) 2014-06-11 2022-05-19 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US9511142B2 (en) * 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20170024087A (ko) 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN107530364A (zh) 2015-04-24 2018-01-02 莱姆派克斯制药公司 治疗细菌感染的方法
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof

Also Published As

Publication number Publication date
LTC3412676I2 (lt) 2022-09-12
MY198204A (en) 2023-08-11
CN103180328A (zh) 2013-06-26
US20160220591A1 (en) 2016-08-04
EP3666778A1 (en) 2020-06-17
WO2012021455A1 (en) 2012-02-16
KR102087313B1 (ko) 2020-03-11
EP2603514A1 (en) 2013-06-19
US20200222434A1 (en) 2020-07-16
JP7227282B2 (ja) 2023-02-21
JP2013535502A (ja) 2013-09-12
BR112013003045B1 (pt) 2021-08-31
IL224564A (en) 2017-02-28
HUE048859T2 (hu) 2020-08-28
HUS1900017I1 (hu) 2019-05-28
CO6680667A2 (es) 2013-05-31
EP3412676B1 (en) 2020-02-12
CY2020019I1 (el) 2020-11-25
US11090319B2 (en) 2021-08-17
BR112013003045A2 (pt) 2016-06-14
US12171772B2 (en) 2024-12-24
US8680136B2 (en) 2014-03-25
JP6854861B2 (ja) 2021-04-07
PL2603514T3 (pl) 2019-04-30
LUC00168I2 (it) 2024-07-01
DK2603514T3 (en) 2018-10-29
HRP20200741T1 (hr) 2020-10-16
JP6266978B2 (ja) 2018-01-24
EP3412676A1 (en) 2018-12-12
CN103180328B (zh) 2016-10-26
ES2691468T3 (es) 2018-11-27
LTC3412676DI2 (lt) 2022-05-10
US20230277571A1 (en) 2023-09-07
AU2011289615B2 (en) 2015-05-07
EP2603514A4 (en) 2014-10-29
NZ607354A (en) 2015-01-30
US11684629B2 (en) 2023-06-27
CY2020020I1 (el) 2020-11-25
US20120040932A1 (en) 2012-02-16
NO2019013I1 (no) 2019-03-28
US20220125813A1 (en) 2022-04-28
US20180214465A1 (en) 2018-08-02
US20190076449A1 (en) 2019-03-14
RU2013104951A (ru) 2014-09-20
NO2019014I1 (no) 2019-03-28
US10639318B2 (en) 2020-05-05
US9296763B2 (en) 2016-03-29
EP3666778B1 (en) 2021-11-10
CY1123208T1 (el) 2020-11-25
AU2011289615A1 (en) 2013-03-21
US10172874B2 (en) 2019-01-08
PL3412676T3 (pl) 2021-04-06
CY2020019I2 (el) 2020-11-25
US10004758B2 (en) 2018-06-26
KR20130099923A (ko) 2013-09-06
JP6602742B2 (ja) 2019-11-06
MY188960A (en) 2022-01-14
HUS1900018I1 (hu) 2019-05-28
KR20190066084A (ko) 2019-06-12
KR20200028043A (ko) 2020-03-13
CA2807546A1 (en) 2012-02-16
US20180207183A1 (en) 2018-07-26
PT3412676T (pt) 2020-05-19
JP2020002178A (ja) 2020-01-09
ES2789177T3 (es) 2020-10-26
SG187757A1 (en) 2013-03-28
CA2807546C (en) 2022-08-23
MX348653B (es) 2017-06-21
EP2603514B1 (en) 2018-07-18
LUC00169I2 (it) 2024-07-01
LTPA2020521I1 (lt) 2020-08-10
PT2603514T (pt) 2018-11-09
CL2013000399A1 (es) 2013-08-23
MX2013001517A (es) 2013-04-29
US10183034B2 (en) 2019-01-22
US20130345172A1 (en) 2013-12-26
DK3412676T3 (da) 2020-05-04
LTPA2020519I1 (lt) 2020-08-10
HUE040086T2 (hu) 2019-02-28
US20250064838A1 (en) 2025-02-27
RU2599791C2 (ru) 2016-10-20
US20180071325A1 (en) 2018-03-15
KR102205755B1 (ko) 2021-01-22
JP2021073212A (ja) 2021-05-13
JP2017052794A (ja) 2017-03-16
CY2020020I2 (el) 2020-11-25
LT3412676T (lt) 2020-07-27
KR101987091B1 (ko) 2019-06-10
US9694025B2 (en) 2017-07-04
RS60310B1 (sr) 2020-07-31

Similar Documents

Publication Publication Date Title
SMT202000248T1 (it) Derivati di estere di acido boronico ciclico e relativi usi terapeutici
ZA201300100B (en) Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
IL238064B (en) A formulation containing smallpox virus, a method for preparing a freeze-dried formulation and their uses
SI2793578T1 (sl) N-arilamidin-substituirani derivati trifluoroetilsulfida kot akaricidi in insekticidi
EP2567259A4 (en) Q tomography method
IL223951A0 (en) (2-aryloxy- acetylamino) phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
ZA201404625B (en) Polycyclic derivatives, preparation method and medical uses thereof
GB201009237D0 (en) New administration method
ZA201407021B (en) Novel thienopyrimidine derivatives,processes for the preparation thereof and therapeutic uses thereof
IL226336A0 (en) A preparation containing insulin, nicotinamide and amino acid
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL239146A0 (en) Aminocyclobutane derivatives, methods for their preparation and their use as drugs
EP2636666A4 (en) TRANS-2 DECENTRIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THEREOF
ZA201309559B (en) Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof
EP2616120A4 (en) ADMINISTRATION APPARATUS, METHOD OF OPERATION THEREFOR, AND METHOD OF ADMINISTRATION
PL393268A1 (pl) Kwas 2-amino-6-dihydroksyborylo-1,2,3,4-tetrahydronaftaleno-2-karboksylowy i sposób jego wytwarzania
EP2565180A4 (en) ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION THEREWITH
SI3412676T1 (sl) Ciklični derivati estra borove kisline, postopek za njihovo pripravo in njihove terapevtske uporabe
IL226388A0 (en) New indolizine derivatives, their preparation and medical use
PL391018A1 (pl) Sole pochodnych cystein i sposób wytwarzania soli pochodnych cystein
HK1179250A (en) Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
PL396622A1 (pl) Pochodne diestrów 4-metylotiofenylowych kwasów 1-amino-2-metylo-propanofosfonowych, sposób wytwarzania pochodnych diestrów 4-metylotiofenylowych kwasów 1-amino-2-metylo-propanofosfonowych oraz zastosowanie pochodnych diestrów 4-metylotiofenylowych kwasów 1-amino-2-metylo-propanofosfonowych
HK1179251A (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
HK1188213A (en) Novel indolizine derivatives, and preparation and therapeutic use thereof